Willow Biosciences Inc ( (TSE:WLLW) ) has shared an update.
Willow Biosciences Inc. has entered into an agreement to sell its wholly-owned operating subsidiary, Epimeron USA, Inc., to a UK-based entity for $3.38 million. This transaction is part of Willow’s strategic review and aims to reduce debt and explore future opportunities to maximize shareholder value. The sale, expected to close by April 30, 2025, is subject to shareholder approval, with major shareholders and directors already committed to supporting the transaction.
More about Willow Biosciences Inc
Willow Biosciences Inc. is a biotechnology company that specializes in developing biomanufacturing processes for producing high-value ingredients across various markets, including pharmaceutical, food and beverage, agriculture, and consumer sectors.
YTD Price Performance: -33.33%
Average Trading Volume: 395,793
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$5.79M
For detailed information about WLLW stock, go to TipRanks’ Stock Analysis page.